26th North American ISSX and 39th JSSX Meeting

26^th North American ISSX and 39^th JSSX Meeting

The Future of Translational Xenobiotic Research

As the foremost organization representing the interests of researchers and educators in DMPK and other related areas of research, the International Society for the Study of Xenobiotics (ISSX) is engaged in multiple activities to support, promote, and advance the science worldwide.  ISSX has an international base of members from more than 45 countries. Members are comprised fairly evenly between academic and industry groups and consist primarily of research scientists and future scientists in toxicology, pharmacology, molecular biology, and other disciplines related to the study of xenobiotics.

During the Conference, Dr. Pin Jiang, Senior Director of DMPK, will present the poster titled "Enhancing Drug-Drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4".

Medicilon team will be present throughout the event. Please stop by our booth and chat how our services and capabilities would support your research needs and expedite your drug discovery and development programs.      

Date: September 15-18, 2024

Location: Hilton Hawaiian Village Waikiki Beach Resort, Honolulu

Medicilon Booth #104

Medicilon DMPK & Bioanalysis Services

DMPK (Drug Metabolism and Pharmacokinetics) considers how the drug is metabolized and processed by the body. DMPK services help support drug developers in understanding the Absorption, Distribution, Metabolism, and Excretion (ADME) processes of compounds or drugs. Pharmacokinetics (PK) is the study of the time course of the ADME of a drug, compound or new chemical entity (NCE) after its administration to the body. ADME test results can be used to predict how the drug will behave in the body and to assess its potential for drug-drug interactions (DDIs) with other drugs. Bioanalytical support plays a vital role during the lead optimization stages. Bioanalytical tools can play a significant role and impact the progress in drug discovery and development. Dramatic increases in investments in new modalities beyond traditional small and large molecule drugs, such as peptides, oligonucleotides, cell and gene therapy, mRNA, PROTAC and XDC, necessitated further innovations in bioanalytical and experimental tools for the characterization of their ADME and PK properties.

Gain access to an integrated network of facilities, including DMPK R&D centers across China and the United States. Medicilon’s DMPK&BA department offers a full range of discovery screening, IND-enabling and clinical drug metabolism and pharmacokinetic platforms and services in the areas: in vitro ADMET, in vivo PK, MetID, Radiolabeled DMPK/ADME, BA, and non-GLP Tox services for both small, large molecule and new modalities drugs, such as proteins, antibodies, peptides, oligonucleotides, cell and gene therapy, mRNA, PROTAC and XDC. We have available all common laboratory animal species such as non-human primates, dogs, mini pigs, mice, rats, rabbits, etc.

Additionally, Medicilon boasts extensive experience in PK studies of ophthalmic drugs and inhaled drug delivery systems, encompassing a range of animal species such as rodents, rabbits, dogs, and monkeys. We offer a variety of delivery methods to accommodate the diverse requirements of drug studies during the preclinical phase.

In Vitro ADMET

❖Liver microsomes / S9 / Hepatocyte metabolic stability

❖CYP450 enzyme inhibition & TDI

❖CYP450 enzyme induction

❖Enzyme phenotype analysis

❖Plasma protein binding

❖Plasma (serum) stability

❖In vitro MetID and metabolic pathways

❖GSH-trapping

❖Whole blood / plasma distribution

❖Permeability and efflux

❖Transporters (P-gp/BCRP/OATs/OCTs/OATPs/MATEs/BSEP/MRPs) BBB penetration,Kp,uu

❖hERG Mini-Ames, Ames

In Vivo PK & Non-GLP Tox

❖Species：Mouse (ICR, C57, balb/c, SCID, Nude mouse), Rat (SD, Wistar), Guinea pig, Mini-pig, Rabbit, Canine (beagle dog), Cynomolgus monkey

❖Administration Routes: Intravenous (IV), Oral (PO), Subcutaneous (SC), Intramuscular (IM), Intraperitoneal (IP), Topical, Transdermal, IT etc.

❖Dose Strategies: Single, multiple and cassette dosing

❖Serial blood microsampling

❖In vivo metabolite identification and quantitation

❖Tissue distribution

❖Mass balance with excretion

❖Pre-formulation screening

❖PK/PD & human PK modeling

❖Tox, MTD, DRF

❖¹²⁵I/¹⁴C/³H labeled isotope drug metabolism and mass balance studies

❖Surgical techniques: Venous cannulation, biliary cannulation, infusion pump, liver/muscle biopsy and implantation

Meet with Medicilon

Subject丨ISSX/JSSX 2024

Company *

Name *

Work Email *

Title*

Verification Code